Thus, these findings strengthen the case for using M1R antagonists for improvement of mitochondrial function, while the ability to suppress excitability of sensory neurons may offer routes for treatment of neuropathic pain as well as simultaneously promoting nerve regeneration in neurodegenerative diseases. The gene discussed is CHRM1; the disease is neurodegenerative disease.